Trials / Terminated
TerminatedNCT02550743
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Phase I Study
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- howard safran · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary goal of this Brown University Oncology Research Group is to determine that a safe dose of BYL719 can be administered with capecitabine and radiation in patients with rectal cancer. Therefore, the threshold of success for this phase I study is to establish safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BYL719 | |
| DRUG | Capecitabine | |
| RADIATION | Radiation |
Timeline
- Start date
- 2016-06-03
- Primary completion
- 2018-11-16
- Completion
- 2018-11-16
- First posted
- 2015-09-15
- Last updated
- 2021-03-12
- Results posted
- 2021-03-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02550743. Inclusion in this directory is not an endorsement.